secwatch.observer — SEC 8-K summary
======================================

Issuer:     Twist Bioscience Corp (TWST)
CIK:        0001581280
Form:       8-K
Filed at:   2021-11-22T23:59:59+00:00
Accession:  0001104659-21-142602
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Twist Bioscience to acquire Abveris for up to $190M in stock and cash
---------------------------------------------------------------------

- Total consideration up to $190M: $150M at close (Twist stock + up to $10M cash) plus up to $40M stock tied to 2022 revenue target.
- Stock price per share collared between $106.10 and $129.68 based on 30-day VWAP before closing.
- Abveris adds in vivo antibody discovery platform (DiversimAb mice) to complement Twist's synthetic library and AI capabilities.
- Acquisition expected to bolster Twist's biopharma antibody design, discovery, and screening services for partners and internal pipeline.
- Deal structured as a merger; shares issued in private placement exempt from registration under Section 4(a)(2) and Rule 506.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1581280/000110465921142602/0001104659-21-142602-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1581280/000110465921142602/tm2133571d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-142602

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer